ARTICLE | Finance
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
By Paul Bonanos, Director of Biopharma Intelligence
October 11, 2024 11:25 PM UTC
Two more IPOs late this week added to the body of evidence for which newly listed biotechs will capture investors’ demand, and which ones are a tougher sell.
Upstream Bio Inc. (NASDAQ:UPB), a developer of therapies in the closely watched inflammation/immune space, enjoyed a first-day aftermarket spike after pricing an upsized IPO at the top of its proposed range, adding 2.5 million shares on top of its goal and raising $255 million. The company opened 26% above its offering price, and finished Friday’s session up $5 (29%) to $22…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653848/upstream-catches-aftermarket-updraft-as-camp4-ipo-gets-muted-reception